BrandWikiReturn

Schott Pharma

Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs.[2][3] Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023.[4] Headquartered in Mainz, Germany,[5][6] the company operates in 14 countries.[7]

History

In 1887, Otto Schott developed borosilicate glass, a form of glassware used to reagent bottles and flasks. From 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials.[8]

Schott Pharma was established as a standalone company in 2022 under the name Schott Pharma AG & Co. KGaA[9][6] through an equity carve-out (or spin-off) from Schott AG, a manufacturer of specialty glass and glass-ceramics.[10][11] In the same year, the company announced their plans to present an IPO, but this was reportedly postponed to 2023 due to the Russian invasion of Ukraine.[5]

In June 2023, Schott Pharma announced plans to hold the IPO in September 2023.[12] This plan was enacted in September, with Schott Pharma going public on the Frankfurt Stock Exchange.[13] The IPO was initially priced at €27 per share,[14][15] and a potential valuation of up to 4.1 billion euros,[16] but increased the share price to €30 the following day.[17][13] The IPO was the largest of the year in Germany.[18][19] In December 2023, Schott Pharma was included in the SDAX.[20] Between September 2024 and March 2025, it was also listed in the MDAX.[21][22]

Production & Manufacturing

The company is headquartered in Mainz and operates in 16 locations across 14 countries.[23]

Europe

North America

South America

Asia

Divisions

Its business is divided into two divisions:

  • Drug Containment Solutions: pharmaceutical vials, cartridges, and glass ampoules[32]
  • Drug Delivery Systems: prefillable glass syringes and syringes made from Cyclic olefin copolymers (COC), suitable for deep-cold medications.[33]

Governance

Schott Pharma is a subsidiary of SCHOTT AG, which holds controlling shares (as of 2023: 77%).[19][17] SCHOTT AG is owned by the Carl Zeiss Foundation.[26]

Schott Pharma is listed on the Frankfurt Stock Exchange's MDAX.[21]

Independent Supervisory Board

The supervisory board for the Schott Pharma AG is as follows:[34][35]

  • Peter Goldschmidt, (chairman)
  • Dr. Wolfram Carius (Executive Vice President of Bayer AG)[36]
  • Eva Kienle (CFO of KWS Saat SE & Co. KGaA)
  • Ann-Kristin Erkens (Corporate Senior Vice President, Financial and Business Controlling at Henkel Adhesive Technologies)
  • Christine Wening (employee stakeholder)
  • Mario Just (employee stakeholder)

Financial Results

References

  1. SCHOTT Pharma Annual Report 2025 (accessed December 11, 2025)^
  2. Fraiser Kansteiner. Glass specialist Schott Pharma touts 2023 sales growth, Serbia expansion and hiring plans Fierce Pharma, 2023-12-23, retrieved 2024-04-08^
  3. EQS-News: SCHOTT Pharma bestätigt Prognose für das Geschäftsjahr 2024 anlässlich seiner Q2-Ergebnisse; Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst 4Investors.de, 2024-05-14, retrieved 2024-06-24^
  4. Theresa Rauffmann. Abhängigkeit vom Geschäft mit Diätspritzen wird zum Problem www.handelsblatt.com, 2024-06-27, retrieved 2024-09-18^
  5. Samir Ibrahim. Schott Pharma startet erfolgreich an der Frankfurter Börse tagesschau.de, 2023-09-28, retrieved 2024-06-24^
  6. Ike Nünchert. SCHOTT Pharma: Carve-Out für ein mögliches IPO Going Public, 2022-08-03, retrieved 2024-06-24^
  7. Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen finanzen.net, 2024-01-24, retrieved 2024-02-28^
  8. Impfstoff-Ampullen – Rohrglas für Lebensretter - VBG Spezial glaskeramik.org, VBG, 2021-07-04, retrieved 2024-02-28^
  9. Kevin Dunleavy. After one year as standalone business, glassmaker Schott Pharma sets course for IPO Fierce Pharma, 2023-09-06, retrieved 2024-06-24^
  10. Fraiser Kansteiner. Glass maker Schott's pharma business sets out on its own. Will an IPO follow? Fierce Pharma, 2022-01-08, retrieved 2024-02-28^
  11. Fraiser Landsteiner. Glass maker Schott's pharma business sets out on its own. Will an IPO follow? Fierce Pharma, 2022-08-01, retrieved 2024-06-24^
  12. William Wilkes. Schott to Hold IPO of Medical Glassware Unit in September: Bloomberg.com Bloomberg.com, 2023-06-22^
  13. Schott Pharma trades up following biggest German IPO since Porsche: Global Capital Global Capital, 2023-10-16^
  14. Swetha Gopinath. Germany's Schott Raises €813 Million in IPO of Medical-Glass Arm www.bloomberg.com, 2023-09-28, retrieved 2024-06-24^
  15. gsp. Schott Pharma geht mit Freshfields an die Frankfurter Börse Extrajournal.Net, 2023-09-29, retrieved 2024-06-24^
  16. Schott Pharma prices IPO at 27 euros per share Reuters, 2023-09-27, retrieved 2024-06-24^
  17. SCHOTT Pharma feiert erfolgreiches Börsendebüt: Erstkurs über Ausgabepreis Finanzen Net, 2023-09-28, retrieved 2024-06-24^
  18. Emma-Victoria Farr, Pablo Mayo Cerqueiro. Schott Pharma shares jump 16% in Frankfurt trading debut reuters.com, Reuters, 2023-09-28, retrieved 2024-02-28^
  19. Schott Pharma startet erfolgreich an der Börse tagesschau.de, 2023-09-28, retrieved 2024-02-28^
  20. Christian Ingerl. Profitabler Small Cap: Zulieferer Schott Pharma bald im SDax Capital, 2023-12-13, retrieved 2024-02-28^
  21. Christoph Ruhkamp. Finanzchefin bringt Schott Pharma in den MDax boersen-zeitung.de, 2024-10-04, retrieved 2024-11-04^
  22. Selection indices: Changes for MDAX and TecDAX Deutsche Börse, 6 March 2025, retrieved 2 March 2026^
  23. Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen finanzen.net, 2024-01-24, retrieved 2024-02-28^
  24. Badische Zeitung. SCHOTT Pharma: Ein globales Kompetenzzentrum in Müllheim Badische Zeitung, 2022-12-02, retrieved 2024-06-24^
  25. Marion Schlegel. SDAX-Neuling Schott Pharma gibt ordentlich Gas: Zahlen kommen gut an www.deraktionaer.de, 2023-12-19, retrieved 2024-06-24^
  26. SCHOTT Pharma baut Produktion in China und Ungarn aus – ZWP online – das Nachrichtenportal für die Dentalbranche www.zwp-online.info, 2022-09-22, retrieved 2024-06-24^
  27. SCHOTT: solides Ergebnis trotz konjunktureller Herausforderungen – ZWP online – das Nachrichtenportal für die Dentalbranche www.zwp-online.info, 2024-02-12, retrieved 2024-06-24^
  28. Gergely Herpai. Schott Pharma's HUF 28 bln Investment Boosts Hungarian Pharmaceutical Manufacturing: Budapest Business Journal Budapest Business Journal, 2024-07-12^
  29. Schott Pharma Begins Construction on Serbia Plant: American Ceramic Society Bulletin American Ceramic Society Bulletin, July 2024^
  30. Schott. SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina: Business Wire (English) Business Wire (English), 2024-03-18^
  31. Joelle Anselmo. Schott Pharma to build $371M syringe factory: Construction Dive Construction Dive, 2024-03-27^
  32. Lea Kaiser. Next generation pharma glass: SCHOTT AG launches FIOLAX® Pro Glass tubing BusinessWire, 2023-10-24, retrieved 2024-06-24^
  33. Schott Pharma rolls out pre-filled polymer syringes for deep-cold medication NS Medical Devices, 2023-05-18, retrieved 2024-02-28^
  34. Jess Mills. Schott appoints Supervisory Board of Schott Pharma Glass International, 2023-05-02, retrieved 2024-06-24^
  35. SCHOTT bestellt Aufsichtsrat der SCHOTT Pharma AG ZWP-online, 2023-05-02, retrieved 2024-06-24^
  36. SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items schott-pharma.com, retrieved 21 October 2025^
  37. SCHOTT Pharma Annual Report 2023/2024 schott.com, retrieved 15 January 2025^